Back to homepage

Tag "ulcerative colitis"

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going

Authors: Eleanor Liu, Nasar Aslam, Gaurav Nigam, Jimmy K Limdi

This narrative review summarizes the current literature regarding the mechanism of action of tofacitinib, data from registrational trials, emerging real-world evidence, and an overview of the most recent safety evidence. The authors explore evolving treatment paradigms and also present a brief overview of the next generation of JAK inhibitors in the pipeline.


Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors

Authors: Keira A Fieldhouse Bsc, Samantha Ukaibe BSc, Erika L Crowley BSc, MSc, Reena Khanna MD, MSc, FRCPC, Ashley O’Toole MD, MHSc, FRCPC, Melinda J Gooderham MD, MSc, FRCPC

This paper reviews all incident cases and exacerbations of IBD reported in the literature during widescale use of IL-17 inhibitors beyond the clinical trials.


Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms

Authors: Benjamin Crooks MA MBBS, Tom Barnes MBBS BSc, Jimmy K Limdi FRCP FACG

This review brings together data reported on VDZ to date for treatment of inflammatory bowel diseases, comprising Crohn’s disease (CD) and ulcerative colitis (UC).


New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance

Authors: Kartikeya Tripathi MD, Joseph D Feuerstein MD

Ulcerative colitis is a chronic idiopathic inflammatory disorder that involves any part of the colon. The authors review the latest evidence on management, treatment, and maintenance.